医学
成本效益分析
内科学
肿瘤科
成本效益
重症监护医学
风险分析(工程)
作者
Saaya Tsutsué,Shinichi Makita,Hiroya Asou,Hiroyuki Matsuda,Reiko Yamaura,Todd D. Taylor
出处
期刊:Future Oncology
[Future Medicine]
日期:2024-04-10
标识
DOI:10.2217/fon-2023-1114
摘要
Aim: Cost-effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (tisa-cel) and lisocabtagene (liso-cel) for treatment of relapsed or refractory large B-cell lymphoma in adult patients after ≥2 lines of therapy in Japan. Materials & methods: Cost-effectiveness analysis was conducted using the partition survival mixture cure model based on the ZUMA-1 trial and adjusted to the JULIET and TRANSCEND trials using matching-adjusted indirect comparisons. Results & conclusion: Axi-cel was associated with greater incremental life years (3.13 and 2.85) and incremental quality-adjusted life-years (2.65 and 2.24), thus generated lower incremental direct medical costs (-$976.29 [-¥137,657] and -$242.00 [-¥34,122]), compared with tisa-cel and liso-cel. Axi-cel was cost-effective option compared with tisa-cel and liso-cel from a Japanese payer's perspective.
科研通智能强力驱动
Strongly Powered by AbleSci AI